An interventional study of Medisinstart in Type 2 Diabetes, sponsored by Apokus AS. Recruiting at 22 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Apokus AS · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 116 studies in Diabetes Mellitus, Type 2 with a site in Norway — 3 open to participants now, 4 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Norway.
Among the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, this one is the 53rd largest by planned enrollment of the 103 interventional ones that give a count, is the only one that started in 2024, is one of 24 with no phase, and was the 113th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 18+
Boehringer Ingelheim · Sites in Norway, United States, Argentina and 48 more countries
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
116 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 56 · Phase 4 11
First in 1996; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 503 across the 103 interventional studies, 2,446 across the 13 observational. Of the 106 that completed or were terminated, 49 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 116 have an industry lead sponsor. The 10 most frequent:
Apokus AS is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Apokus AS has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes Mellitus, Type 2 with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06273657Apokus ASEffects of Medisinstart for Type 2 Diabetes | 2027-02 |
| NCT07361640Oslo University HospitalDiaMester Pilot RCT: E-health Lifestyle Program for Type 2 Diabetes | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up appointments with a pharmacist. The aim of the service is to promote correct medication use and increase patient adherence. The effect of Medisinstart has previously been studied among patients starting a new cardiovascular drug. The aim of the project is to map the effects of Medisinstart among patients starting a new medication for type 2 diabetes. Knowledge about the effects of Medisinstart is important in order to maximize the benefits of the service for patients and society. The project is being conducted as a randomized controlled trial among adult patients starting a new medication for type 2 diabetes. The intervention group receives Medisinstart, while the control group only receives prescription dispensing as normal. Data collection includes HbA1c analysis in blood samples and responses to questionnaires. HbA1c is an established measure of glycemic control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Medisinstart
Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.
HbA1c
Change in HbA1c-level from baseline to 6 months after initiation of a new medication for type 2 diabetes.
Time frame: At baseline and 6 months after initation of the new medication for type 2 diabetes.
HbA1c
Change in HbA1c-level from baseline to 12 months after initiation of a new medication for type 2 diabetes.
Time frame: At baseline and 12 months after initation of the new medication for type 2 diabetes.
Self-reported adherence
Adherence will be measured by a Norwegian translation of the MARS-5 questionnaire. The total MARS-5 score can have values from 5-25, with higher scores indicating higher adherence.
Time frame: 6 and 12 months after initiation of the new medication for type 2 diabetes
Self-reported adherence
Adherence will be measured by a Norwegian translations of the question: "People often miss taking doses of their medicines, for a wide range of reasons. Have you missed any doses of your new medicine the last week?" The question will be answered by yes/no.
Time frame: 6 and 12 months after initiation of the new medication for type 2 diabetes
Frequency of medication-related problems
Pharmacists will report identified medication-related problems (MRPs) in a structured self-developed electronic questionnaire. The MRP categories in the questionnaire are based on the MRP classification presented by Ruths et al. (Tidsskr Nor Laegeforen. 2007 Nov 29;127(23):3073-6). The different MRP categories will be reported as identified or not identified in the consultations.
Time frame: At the first and second Medisinstart consultations and 12 months after initiation of the new medication for type 2 diabetes
Patients' beliefs about their medicines
Patients' beliefs about their medicines will be measured by a validated Norwegian translation of the Beliefs about Medicines Questionnaire (BMQ). The BMQ general comprises three subscales, Harm, Overuse and Benefit, and the total score of each subscale ranges from 4 to 20. The BMQ specific comprises two subscales, Concerns and Necessity, and the total score of each subscale ranges from 5 to 25. Higher scores indicate stronger beliefs in the concepts represented by the subscale.
Time frame: At baseline and 6 months after initation of the new medication for type 2 diabetes
Diabetes Self-Management
Diabetes Self-Management will be measured by a validated Norwegian translation of the Diabetes Self-Management Questionnaire-Revised (DSMQ-R). The scores are summed and transformed into a 1-10 scale for each of the following activities: "eating behavior", "medication use", "glucose monitoring", "physical activity" and "interaction with treating physician/healthcare professional". In addition, a total score is calculated as an overall measure of the patient's diabetes self-management. Values in the upper part of the scale indicate good self-care.
Time frame: 12 months after initiation of the new medication for type 2 diabetes
Diabetes Treatment Satisfaction
Diabetes Treatment Satisfaction will be measured by a validated Norwegian translation of the Diabetes Treatment Satisfaction Questionnaire (DTSQ). The scores range from 0 to 36 where higher scores indicate greater satisfaction with treatment.
Time frame: At baseline and 6 and 12 months after initiation of the new medication for type 2 diabetes
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 36 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Feb 2026 → Feb 2027 and completion Feb 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Apokus AS